Guardant Health and Nuvalent entered a multi-year strategic collaboration to develop and potentially commercialize oncology companion diagnostics using Guardant’s liquid and tissue biopsy portfolio. The companies will support Nuvalent global clinical oncology studies and evaluate Guardant assays as companion diagnostics to support regulatory submissions. The collaboration also extends to commercialization planning across key global markets if Nuvalent’s investigational candidates receive approvals. Nuvalent’s pipeline includes investigational therapies for ALK-positive NSCLC, with a recent FDA filing for neladalkib. For precision oncology developers, the pact signals continued emphasis on integrating biomarker strategies directly into late-stage development and labeling pathways.